Sutro Biopharma has been granted a patent for antibodies that target B-cell maturation antigen (BCMA) and its variants, with potential therapeutic and diagnostic applications. The patent covers an isolated IgG antibody that specifically binds to BCMA, offering a promising avenue for medical research and treatment development. GlobalData’s report on Sutro Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sutro Biopharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Sutro Biopharma's grant share as of May 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies binding to b-cell maturation antigen (bcma)
A recently granted patent (Publication Number: US11993658B2) discloses an isolated antibody of the IgG class that specifically binds to B-cell maturation antigen (BCMA). The antibody comprises various regions, including CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, of the VH-VL pair of specific sequences. Additionally, the patent claims cover variants of the antibody with limited amino acid substitutions, constant region domains, humanized antibodies, aglycosylated antibodies, and antibody fragments such as FIT, Fab, F(ab'), scFv, and scFv-Fc fragments.
Furthermore, the patent includes claims for a kit containing the antibody and instructions for use, a pharmaceutical composition with a pharmaceutically acceptable carrier, and a method for treating BCMA-expressing cancers in subjects by administering the antibody or pharmaceutical composition. The disclosed method targets diseases like leukemia, lymphoma, multiple myeloma, plasmacytoid dendritic cell tumors, B-cell lineage malignancies, and plasma cell neoplasms, including specific subtypes like diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma, plasmablastic lymphoma, and follicular lymphoma. The antibody's efficacy is highlighted by its association rate constant (ka) when binding to human BCMA at a specific temperature, emphasizing its potential therapeutic value in treating BCMA-expressing cancers.
To know more about GlobalData’s detailed insights on Sutro Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
